Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.47 |
| ▸ | TERT | O14746 | 3/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 2/20 | 0.34 |
| ▸ | VEGFA | P15692 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3431905 | 1.00 | S1PR1 (0.47) | S1PR1S1PR3S1PR5TERTS1PR4 | |
| SCHEMBL3424378 | 1.00 | S1PR1 (0.47) | S1PR1S1PR3S1PR5TERTS1PR4 | |
| SCHEMBL3429297 | 0.89 | TERT (0.46) | S1PR1S1PR3S1PR5TERTS1PR4 | |
| SCHEMBL3429336 | 0.89 | TERT (0.46) | S1PR1S1PR3S1PR5TERTS1PR4 | |
| SCHEMBL3429407 | 0.89 | TERT (0.46) | S1PR1S1PR3S1PR5TERTS1PR4 | |
| SCHEMBL3430851 | 0.87 | S1PR1 (0.47) | S1PR1S1PR3S1PR5TERTS1PR4 | |
| SCHEMBL3424382 | 0.87 | S1PR1 (0.47) | S1PR1S1PR3S1PR5TERTS1PR4 | |
| SCHEMBL3431907 | 0.87 | S1PR1 (0.47) | S1PR1S1PR3S1PR5TERTS1PR4 | |
| SCHEMBL2116271 | 0.84 | S1PR1 (0.44) | S1PR1S1PR3S1PR5TERTS1PR4 | |
| SCHEMBL3429337 | 0.83 | TERT (0.46) | S1PR1S1PR3S1PR5TERTS1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | S1PR1 4208/4885S1PR3 4315/4885S1PR5 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.